

PF-PTD-71

Synonyms       Carbohydrate Antigen 15-3         Clinical Indication       Serum CA15-3 is raised in breast and other adenocarcinomas, especially with distant metastasis. Levels are rarely raised in patients with localised breast cancer.         Part of Profile / See Also       used in the monitoring treatment of patients with advanced breast cancer.         Request Form       Combined Pathology manual Blood form or ICE request         Availability / Frequency of Analysis       Referred test: Analysed by Biochemistry, Charing Cross Hospital, if specific criteria met.         Turnaround Time       1 week samples processed locally. 2 weeks samples processed at Charing Cross.         Patient Preparation       Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.         Sample Requirements       Serum and plasma         Yolume       1 ml         Acceptable Containers       Serum and plasma         Yellow top (SST) tube       Imitiant paediatric orange top (lithium-heparin) tube         Imitiant paediatric green top (lithium-heparin)       Imitiant paediatric green top (lithium-heparin)         Patient Preparation       Imitiant paediatric green top (lithium-heparin)         Patient Preparation       Imitiant paediatric green top (lithium-heparin)         Acceptable Containers       Imitiant paediatric green top (lithium-heparin)         Imi       Imi	CA15-3	MEDICAL 7880 Accredited to ISO 15189:2012
Section of CAS>-5 is raised in press and other adentical childras, especially with is stated in the ast and other adentical childras, especially with is stated in the monitoring treatment of patients with localised breast cancer.Part of Profile / See Also Combined Pathology manual Blood form or ICE requestRequest FormCombined Pathology manual Blood form or ICE requestAvailability / Frequency of AnalysisReferred test: Analysed by Biochemistry, Charing Cross Hospital, if specific criteria met.Turnaround Time1 week samples processed locally. 2 weeks samples processed at Charing Cross.Patient PreparationSamples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.Sample Requirements 	Synonyms	Carbohydrate Antigen 15-3
Part of Profile / See Also       Combined Pathology manual Blood form or ICE request         Request Form       Combined Pathology manual Blood form or ICE request         Availability / Frequency of       Referred test: Analysed by Biochemistry, Charing Cross Hospital, if specific criteria met.         Turnaround Time       1 week samples processed locally. 2 weeks samples processed at Charing Cross.         Patient Preparation       Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.         Sample Requirements       Serum and plasma         Yolume       1 ml         Acceptable Containers       Serum and plasma         Volume       1 ml         Comparison       Green top (lithium-heparin) tube         Image: Serum of the serue of the	Clinical Indication	distant metastasis. Levels are rarely raised in patients with localised breast cancer.
Request FormCombined Pathology manual Blood form or ICE requestAvailability / Frequency of AnalysisReferred test: Analysed by Biochemistry, Charing Cross Hospital, if specific criteria met.Turnaround Time1 week samples processed locally. 2 weeks samples processed at Charing Cross.Patient PreparationSamples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.Sample Requirements Specimen TypeSerum and plasma 1 mlAcceptable ContainersImiAcceptable ContainersImiContainersSerum and plasma (Serum and plasma) (Serum an		Used in the monitoring treatment of patients with advanced breast cancer.
Availability / Frequency of AnalysisReferred test: Analysed by Biochemistry, Charing Cross Hospital, if specific criteria met.Turnaround Time1 week samples processed locally. 2 weeks samples processed at Charing Cross.Patient PreparationSamples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.Sample Requirements VolumeSerum and plasma 1 mlAcceptable ContainersSerum and plasma Green top (lithium-heparin) tube impaediatric orange top (lithium-heparin) impaediatric green top (lithium-heparin)		
Analysis       criteria met.         Turnaround Time       1 week samples processed locally. 2 weeks samples processed at Charing Cross.         Patient Preparation       Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.         Sample Requirements       Serum and plasma         Volume       1 ml         Acceptable Containers       Serum and plasma         Volume       1 ml         Image: Serum and plasma       Yellow top (SST) tube         Image: Serum and plasma       Yellow top (SST)         Image: Serum and plasma	Request Form	Combined Pathology manual Blood form or ICE request
Patient PreparationCross.Patient PreparationSamples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.Sample RequirementsSerum and plasmaSpecimen TypeSerum and plasmaVolume1 mlAcceptable ContainersImlCross.Cross.ContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersImlContainersIml <t< th=""><th></th><th></th></t<>		
doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.         Sample Requirements         Specimen Type       Serum and plasma         Volume       1 ml         Acceptable Containers       Imition         Serum and plasma       Serum and plasma         Imition       Imition         Support       Serum and plasma         Imition       Imition         Support       Serum and plasma         Imition       Imition         Support       Imition         Imition	Turnaround Time	
Specimen Type       Serum and plasma         Volume       1 ml         Acceptable Containers       Import and plasma         Import and plasma       Import and plasma         Import and plasma <thimport and="" plasma<="" th="">       Import and plasma<th>Patient Preparation</th><th>doses (i.e. &gt; 5 mg/day) until at least 8 hours following the last biotin</th></thimport>	Patient Preparation	doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin
Volume     1 ml       Acceptable Containers     Image: Containers       Image: Containers     Image: Container	Sample Requirements	
Acceptable Containers  Example Containers  Exa	Specimen Type	Serum and plasma
Yellow top (SST) tube         Yellow top (lithium-heparin) tube         Image: State of the	Volume	1 ml
	Acceptable Containers	Green top (lithium-heparin) tube
Reference Range & Units Less than 32 ku/L (Referral Lab Charing Cross)	Reference Range & Units	Less than 32 ku/L (Referral Lab Charing Cross)

Less than 34.5 ku/L (Roche)

Typically, no high-dose hook effect can be observed at CA 153 concentrations up to 20000kU/L. However due to the heterogeneous nature of the CA 153

Version 1.3 / September 2023

Interferences



PF-PTD-71

	antigen a high dose hook effect below this value cannot be completely excluded. In cases of an unexpected low result, the sample should be diluted 1:10 and tested again. Applies to local analysis on Roche analyser only.
Interpretation & Clinical	Half-life in serum: Unknown.
Decision Value (if applicable)	CA15-3 levels may be raised in benign liver disease and possibly benign breast disease. Elevations are seen in a number of carcinomas e.g. stomach, colon, gall bladder, pancreas, oesophagus, liver and lung.
References	Roche kit insert.
Test code	CA153 C15X
Lab Handling	Aliquot and store at 4°C for samples analysed locally. Aliquot and freeze at -20°C for samples analysed at Charing Cross.
	Serum and plasma stable at 2-8°C for 5 days.